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ABSTRACT
Donor lymphocyte infusion (DLI) results in complete cytogenetic remission (CCR) of relapsed chronic-phase
chronic myeloid leukemia (CML-CP) after allogeneic stem cell transplantation (SCT) in up to 80% of patients. The
main complication of DLI is graft-versus-host disease (GVHD). Decreasing the dose of DLI is associated with less
GVHD but also with a longer interval between treatment and CCR. We postulated that combining -interferon
(-IFN) with DLI would enable us to decrease the dose of DLI, thereby limiting GVHD, and at the same time to
decrease the interval between DLI and CCR for patients with either a hematologic or cytogenetic relapse. For
molecular relapses, we hypothesized that because of a lower tumor load, very low doses of DLI without-IFN could
be an effective treatment. Two groups of CML-CP patients treated with DLI at a very low dose of 0.5 to 1.0 107
mononuclear cells per kilogram, containing 2 to 6 106 CD3T cells per kilogram, were analyzed: 13 patients with
a cytogenetic or a hematologic relapse after allogeneic SCT (group A) were treated with additional -IFN therapy
at a dose of 3 106 U 5 d/wk, and 8 patients with a molecular relapse were treated without-IFN (group B). Twelve
patients from group A reached a CCR. The median interval between DLI and CCR was 7 weeks (range, 5-18 weeks)
for group A. All patients with a CCR reached complete donor chimerism at a median of 10 weeks after DLI (range,
6-121 weeks). Eleven patients reached molecular remission at a median of 15 weeks after DLI (range, 8-34 weeks).
In group B, all patients reached a molecular remission at a median of 14 weeks (range, 12-29 weeks). Five patients
from group A developed acute GVHD grade II to IV and extensive chronic GVHD. In group B, 1 patient developed
acute GVHD grade II to IV and subsequently developed extensive chronic GVHD. With a median follow-up of 62
months, 10 patients in group A are alive and in continuous CCR. One patient had a molecular relapse, for which
she successfully received additional DLI; another patient reached molecular remission only after 5 doses of DLI.
Two patients from group A died of a gram-negative sepsis, and 1 died of an acute myocardial infection. In group B,
all patients are alive and in molecular remission with a median follow-up of 20 months. One patient’s disease
progressed but was successfully treated with DLI plus -IFN. In conclusion, very-low-dose DLI in combination
with -IFN as treatment for cytogenetic or hematologic relapses of CML-CP after allogeneic SCT reduced the
interval to obtain a CCR with acceptable GVHD when compared with the literature. Patients with a CCR also
reached complete donor chimerism and complete molecular remissions. For patients with a molecular relapse,
very-low-dose DLI alone is sufficient to induce molecular remissions in most patients and is associated with limited
GVHD.
© 2004 American Society for Blood and Marrow Transplantation
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-Interferon and CML
BNTRODUCTION
Allogeneic stem cell transplantation (SCT) is the
nly curative treatment for patients with chronic my-
loid leukemia (CML) [1]. Relapse rates after alloge-
eic SCT vary from 20% to 50%, depending on
-cell depletion of the graft [2]. Relapses of CML
fter allogeneic SCT can successfully be treated with
onor lymphocyte infusions (DLI), resulting in com-
lete remissions (CR) in up to 80% of patients [3-13].
he likelihood of achieving CR depends on the extent
nd type of relapse. Molecular or cytogenetic relapses
f chronic phase (CP) CML respond more frequently
han hematologic relapses [4-7,13], whereas patients
ith relapses in accelerated or blastic phase have a
elatively low likelihood of responding to DLI [8,10].
he antileukemic response is often associated with the
evelopment of graft-versus-host disease (GVHD),
specially when a high initial cell dose is given [14].
ow-dose DLI with up to 107 CD3 T cells per
ilogram body weight of the recipient is associated
ith a lower incidence of severe GVHD but also with
long interval between intervention and achievement
f a complete cytogenetic remission (CCR). The me-
ian interval between DLI at a dose of 107 CD3 T
ells per kilogram for cytogenetic or hematologic re-
apse and CCR was reported to be 14 weeks (range,
-19 weeks) by Mackinnon et al. [6] and to be up to 22
eeks by Dazzi et al. [7]. This long interval may put
he patient at risk for disease progression [4-8,10,13].
herefore, low-dose DLI is often followed by higher
oses when an increase in tumor load is observed after
he initial dose [6,7]. However, although higher doses
f DLI (107 CD3 T cells per kilogram) seem to
ecrease the interval to CCR, dose escalation may also
e accompanied by more severe GVHD and a higher
reatment-related mortality [14].
In earlier studies, -interferon (-IFN) was coad-
inistered with DLI because of a possible enhance-
ent of the immune response against the leukemic
ells [3]. Multivariate analysis of larger groups of pa-
ients with relapsed CML treated with DLI did not
how signiﬁcant differences in response rate with or
ithout additional -IFN therapy. However, the cell
ose infused in most of the patients described in these
tudies was high (median, 3-5  108 mononuclear
ells [MNC] per kilogram) [4,5]. Previously, we have
hown that -IFN increased the efﬁcacy of generating
eukemia-reactive CTL in vitro [15]. Others described
n enhanced immune response in vivo by -IFN [16].
limited number of patients with a relapse of CML
fter allogeneic SCT entered remission after treat-
ent with -IFN alone [17]. Moreover, -IFN has
irect antiproliferative effects on CML cells in vitro
18]. More recently, we demonstrated that -IFN
ncreased the sensitivity of leukemic cells to Fas-in-
uced apoptosis, mediated by recruitment of leukemic r
B&MTells from the resting G0 compartment to the G1
hase [19]. On the basis of these ﬁndings, we analyzed
n this study whether the addition of -IFN to very-
ow-dose DLI (0.5-1.0  107 MNC per kilogram)
ontaining approximately 2 to 6  106 CD3 T cells
er kilogram can potentiate and accelerate the im-
une response against CML cells with acceptable
VHD in patients with a hematologic or cytogenetic
elapse after allogeneic SCT. Patients with a molecu-
ar relapse of CML were treated with similar very-
ow-dose DLI without -IFN, because we hypothe-
ized that DLI alone might eradicate the relatively low
umor load in these patients. In case of progression of
he disease in the latter patients, -IFN was added to
he DLI.
In this study, we demonstrate that for patients
ith a hematologic or cytogenetic relapse of CML-
P, the combination of very-low-dose DLI (0.5-1.0
07 MNC per kilogram) with -IFN at a dose of 3 
06 IU 5 d/wk resulted in a short interval between
LI and CCR and an acceptable incidence of GVHD.
or patients with a molecular relapse, we conﬁrmed
hat very-low-dose DLI alone is sufﬁcient to induce
olecular remission in most patients, with a low in-
idence of GVHD.
ATERIALS AND METHODS
atients
Between January 1994 and January 2003, 21 se-
uential patients with a relapse after allogeneic SCT
or CML-CP were treated with DLI. Two groups of
atients were treated: between January 1994 and Jan-
ary 2000, 13 patients with a cytogenetic or a hema-
ologic relapse (group A) and between January 2000
nd January 2003, 8 patients with a molecular relapse
group B) received DLI. Patient characteristics are
hown in Table 1. The deﬁnitions of relapses are
escribed below.
ransplantation and Follow-up
As a conditioning regimen, patients with HLA-
dentical sibling donors received cyclophosphamide
0 mg/kg intravenously on days 6 and 5 and 9 Gy
f total body irradiation on day 1. Total body irra-
iation was 2  6 Gy on days 1 and 0 for patients
ith matched unrelated donors (URD) or with HLA-
ismatched sibling donors. The stem cell graft was
-cell depleted by adding 10 mg of Campath-1G
Therapeutic Antibody Centre, Oxford, UK) or 20 mg
f Campath-1H to the graft [20]. Recipients of
atched URD grafts also received Campath-1G or
1H 5 mg/d in vivo on days 8 to 4 and cyclospor-
ne 3 mg/kg intravenously from day 1.
After transplantation, peripheral blood, bone mar-
ow, or both were collected at ﬁxed time points for
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2orphologic examination and cytogenetic analysis,
nd from January 1, 2000, they were also collected for
solation of messenger RNA and DNA to quantify
CR/ABL transcripts and to analyze donor chimer-
sm, respectively (see “Response Evaluation”). This
as performed at intervals of 3 months during the ﬁrst
years and at longer intervals thereafter unless there
as a clinical suspicion of relapse. For patients treated
efore January 1, 2000, molecular and chimerism
nalysis was performed retrospectively from frozen
amples. A molecular relapse was deﬁned as the reap-
earance of BCR/ABL transcripts in blood or bone
arrow or a 1-log increase when patients remained
CR/ABL positive after transplantation on at least 2
onsecutive occasions. A cytogenetic relapse was de-
ned as the reappearance of the Philadelphia chromo-
ome in the bone marrow assessed with standard cy-
ogenetics or 1% positivity by using ﬂuorescence in
itu hybridization (FISH). A hematologic relapse was
eﬁned as the reappearance of the characteristic mor-
hologic features of CML.
reatment Protocol
Patients were treated with a DLI protocol that was
pproved by the Leiden ethical committee for medical
esearch. Treatment for group A started immediately
fter the diagnosis of a relapse was made and consisted
f -IFN subcutaneously (Roferon; Roche, Mijdrecht,
6
able 1. Clinical Characteristics of Patients with CML Relapsing after
Patient
No.
Sex
(Patient/Donor)
Source of
Stem Cells Donor
1 F/F BM Sibli
2 M/M BM Sibli
3 M/M BM Sibli
4 M/M BM Sibli
5 F/M PB Sibli
6 M/F PB Sibli
7 M/M PB URD
8 M/M BM URD
9 M/M BM Sibli
10 F/F BM Niec
11 M/F BM URD
12 F/F PB Sibli
13 F/M PB Sibli
14 M/F PB Sibli
15 F/M PB Sibli
16 M/M PB Sibli
17 F/F BM URD
18 F/F PB Sibli
19 F/M PB Sibli
20 M/M PB Sibli
21 F/M PB URD
indicates male; F, female; BM, bone marrow; PB, peripheral blo
HLA-matched unrelated donor.
HLA phenotypically identical.he Netherlands) at a dose of 3  10 IU 5 d/wk A
06ollowed 2 to 4 weeks later by DLI at a dose of 107
NC per kilogram containing 4 to 6  106 CD3 T
ells per kilogram. Group B was treated by DLI alone
t a dose of 107 MNC per kilogram. Patients with
RD received 5  106 MNC per kilogram. After
nformed consent, MNC were harvested from the
tem cell donor by using a Cobe Spectra apheresis
ystem (Cobe BCT, Inc., Lakewood, CO). MNC were
ounted, 107 MNC per kilogram were administered
irectly, and residual cells were cryopreserved in liq-
id nitrogen to allow administration of 3  107 viable
NC per kilogram after thawing for a second DLI in
ase of no response to the ﬁrst infusion.
esponse Evaluation
After DLI, peripheral blood and bone marrow
ollections were performed every 4 weeks during the
rst 3 months and at longer intervals thereafter to
llow morphologic examination, cytogenetic analysis,
nd isolation of RNA and DNA for BCR/ABL quan-
iﬁcation and analysis of chimerism, respectively.
ytogenetic Analysis
This was performed by conventional banding
echniques and with FISH. FISH was performed as
escribed previously, with minor modiﬁcations [21].
rieﬂy, ﬂuorescent-labeled probes for the BCR and
eic SCT (AlloSCT)
Age at
SCT (y)
Months from AlloSCT
to Relapse
Type of
Relapse
29 23 Cytogenetic
38 8 Cytogenetic
43 17 Cytogenetic
40 9 Cytogenetic
36 19 Cytogenetic
38 18 Cytogenetic
33 12 Cytogenetic
28 27 Hematologic
27 11 Hematologic
45 21 Hematologic
29 7 Hematologic
48 9 Hematologic
37 66 Hematologic
21 12 Molecular
45 12 Molecular
26 13 Molecular
40 12 Molecular
48 5 Molecular
45 11 Molecular
44 23 Molecular
19 17 Molecular
D, unrelated donor.Allogen
Type
ng
ng
ng
ng
ng
ng
*
ng
e†
ng
ng
ng
ng
ng
ng
ng
ng
od; URBL genes (LSI-bcr/abl or LSI-bcr/abl ES; Vysis Inc.,
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-Interferon and CML
Bowners Grove, IL) identiﬁed the BCR/ABL fusion
ene in interphase or metaphase nuclei in CML cells
hen the signals were juxtaposed.
olecular Analysis of BCR/ABL Transcripts
This was performed by quantitative real-time
olymerase chain reaction (PCR) analysis as described
reviously [22]. Brieﬂy, total RNA was isolated from
one marrow and peripheral blood aspirates by using
rizol (Invitrogen, Carlsbad, CA), according to the
anufacturer’s instructions. Random primed comple-
entary DNA (cDNA) was synthesized from 1 g of
otal RNA by using the ﬁrst-strand cDNA synthesis
it for reverse transcriptase-PCR (AMV; Roche, In-
ianapolis, IN). Quantitative real-time PCR for BCR/
BL was performed on an ABI/Prism 7700 Sequence
etector System (Applied Biosystems, Foster City,
A). Expression of BCR/ABL transcripts was com-
ared with a serial dilution of CML cells in MNC
btained from a healthy individual. The amount of
orfobilinogendehydrogenase (PBGD) [22] expres-
ion in the samples was determined to correct for
ifferences between samples and runs. To correct for
he total amount of ampliﬁed cDNA, the ratio be-
ween absolute numbers of BCR/ABL transcripts and
BGD transcripts was calculated. The limit of detec-
ion for this assay was a BCR/ABL-PBGD ratio of
.105.
himerism Analysis
Donor chimerism was quantiﬁed in peripheral
lood leukocytes, bone marrow cells, or both, as de-
cribed recently [23]. For sex-mismatched transplan-
ations, chimerism was analyzed by FISH with X- and
-chromosome–speciﬁc probes. The probes used to
dentify the X- and Y-chromosome were a centro-
ere–X-speciﬁc DNA probe (pBamX5) and a DNA
robe speciﬁc for the heterochromatic region of the
-chromosome (pY3.4). For sex-matched transplanta-
ions, genomic DNA was isolated with a Puregene
NA isolation kit (Gentra Systems, Minneapolis,
N). Donor and patient were screened for informa-
ive polymorphic genomic markers by using the Amp-
LSTR Proﬁler Plus ID Ampliﬁcation Kit (Applied
iosystems). Posttransplantation samples were ana-
yzed with 2 polymorphic markers informative for the
umber of hematopoietic cells from patient origin.
mpliﬁcation was performed on a 96-well GeneAmp
CR System 9700 thermocycler (Applied Biosystems)
y using AmpliTaq Gold DNA Polymerase (Applied
iosystems). PCR products were analyzed on an ABI
rism 310 Genetic Analyzer with GeneScan Analysis
oftware version 2.1 (Applied Biosystems). The sensi-
ivity for most markers was 1%. D
B&MTtudy End Points and Statistical Analysis
Data were analyzed as of May 1, 2003. The me-
ian follow-up was 51 months (range, 14.5-102
onths) for group A and 21 months (range, 9-35
onths) for group B. Overall survival was estimated,
y using the Kaplan-Meier method, from the date of
rst infusion of donor cells until death from any cause
r last follow-up evaluation. Patients still alive at the
ime of analysis were censored at the last follow-up
valuation date. Complete cytogenetic response was
eﬁned by the absence of the Philadelphia chromo-
ome by standard cytogenetics or 1% positivity with
ISH. Whenever cytogenetic analysis was not per-
ormed, CCR was deﬁned by the absence of BCR/
BL transcripts with real-time quantitative PCR anal-
sis. Complete donor chimerism was deﬁned as99%
uantiﬁed donor markers and1% recipient markers.
omplete molecular remission was deﬁned by the
bsence of BCR/ABL transcripts as measured by
CR. Toxicity was graded according to the World
ealth Organization toxicity scale. Acute GVHD was
cored according to the Glucksberg criteria [24], and
hronic GVHD was scored according to the Shulman
riteria [25].
ESULTS
atients
Thirteen patients with a cytogenetic or hemato-
ogic relapse (group A; patients 1-13) and 8 patients
ith a molecular relapse (group B; patients 14-21)
ntered the study. Patient characteristics are shown in
able 1. The patients ranged in age at the time of
CT from 27 to 48 years (median, 38 years) in group
and from 19 to 48 years (median, 42 years) in group
. The time interval from allogeneic SCT to relapse
anged from 7 to 66 months (median, 17 months) for
roup A and from 5 to 23 months (median, 12
onths) for group B. In group A, 3 patients received
RD transplants, and in group B 2 patients had an
RD. In 2 patients (patients 5 and 13), -IFN was
nitially reduced in dose but was ﬁnally stopped after
0 and 54 weeks, respectively, because of severe ﬂulike
ymptoms.
ytogenetic Response
Twelve of 13 patients from group A entered a
CR. The median interval between DLI and CCR
as 7 weeks (range, 5-18 weeks; Table 2). Patient 5
eveloped a second (molecular) relapse after discon-
inuation of -IFN because of side effects. She re-
eived additional doses of DLI, and this was followed
y a second molecular remission. Patient 13 did not
each cytogenetic remission until after a ﬁfth dose of
LI. This patient did not receive -IFN continuously
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2ecause of side effects, and eventually -IFN was
topped.
CR/ABL and Chimerism Response
Twelve of 13 patients from group A reached com-
lete donor chimerism at a median of 10 weeks (range,
-121 weeks), and 11 of them reached a complete
olecular remission at a median of 15 weeks (range,
-34 weeks; Table 2; Figure 1). Seven of 8 patients
rom group B reached a molecular remission at a
edian of 14 weeks (range, 12-29 weeks; Table 2).
atient 14 was initially treated with DLI alone (107
NC per kilogram) without -IFN, according to
rotocol, but because of rapid progression from a
olecular relapse to a hematologic relapse, the patient
as treated with 3  107 MNC per kilogram and
-IFN 13 weeks after the ﬁrst DLI, resulting in com-
lete molecular remission. Donor chimerism was al-
ays mixed at relapse for patients from group A. Ten
atients from group A converted to complete donor
himerism after 1 dose of DLI; 2 patients needed
dditional doses. Patient 5 received 2 doses, and pa-
ient 13 needed 5 doses of DLI (total cell dose, 7.4 
08 MNC per kilogram) to a obtain complete donor
himerism (Figure 1). Complete donor chimerism was
able 2. Results of DLI Treatment in Patients with Relapsing CML a
Patient
No.
Chemotherapy
Before DLI MNC/kg
DLI-CCR
(wk)
DL
R
1 No 1  107 6
2 No 1  107 6
3 No 1  107 6
4 No 1  107 6
5 No 1  107* 15
6 No 1  107 5
7 No 0.5  107 10
8 No 1  107 16
9 No 1  107 18
10 Hydrea 0.6  107 NR
11 Hydrea 1  107 7
12 No 1  107 9
13 Hydrea 1  107* NA
edian 7 (5-18) 1
14 No 1  107
3  107
15 No 1  107
16 No 1  107
17 No 5  106
18 No 1  107
19 No 1  107
20 No 1  107
21 No 5  106
edian 1
NC indicates mononuclear cells; DLI-CCR, interval between ﬁr
remission; NA, not assessed.
Needed additional doses of DLI.
Measured from the date of ﬁrst DLI. Patient 14 progressed to a h
-IFN induced complete molecular remission.resent at the time of molecular relapse in 6 patients m
08rom group B. The other 2 patients (patients 18 and
0) converted to complete donor chimerism after DLI
t 5 and 12 weeks, respectively.
igure 1. Kinetics of donor chimerism in patients with a relapse of
ML after allogeneic SCT treated with DLI. Kinetics of donor
himerism for group A (cytogenetic or hematologic relapse; patients
-13) and group B (molecular relapse; patients 14-21); between
rackets is the ﬁrst week of complete donor chimerism. E indicates
geneic SCT
ular
n
DLI-Complete
Donor Chimerism
(wk)
Grade
Acute
GVHD
Grade
Chronic
GVHD Alive
10 0 0 Yes
6 II 0 Yes
6 0 0 Yes
7 II Limited No
15 0 0 Yes
9 0 0 Yes
10 III Extensive No
16 0 Limited Yes
10 IV Extensive Yes
NR I Extensive No
7 III 0 Yes
9 I 0 Yes
121† 0 0 Yes
) 10 (6-121)
0 0 Yes
0 0 Yes
0 0 Yes
I Limited Yes
III Extensive Yes
0 0 Yes
0 0 Yes
I 0 Yes
9)
or leukocyte infusion and complete cytogenetic response; NR, no
ogic relapse after the ﬁrst DLI; subsequent treatment with DLI fter Allo
I-Molec
emissio
(wk)
14
8
18
34
15†
9
10
20
26
NR
20
9
NR
5 (8-34
29
16
13
13
12
14
17
26
12
4 (12-2
st don
ematolixed donor chimerism; F, complete donor chimerism.
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BVHD and Other Toxicity
Seven of 13 patients from group A developed
cute GVHD: 2 patients had grade I, 2 patients had
rade II, 2 patients had grade III, and 1 patient had
rade IV. Two patients developed limited chronic
VHD, and 3 developed extensive chronic GVHD
Table 2). GVHD occurred both before and after
CR was reached at a median of 8 weeks (range, 3-28
eeks) after DLI (data not shown). In group B, 3
atients developed acute GVHD: 2 patients developed
rade I, and 2 patients developed grade III aGVHD.
he latter patients also developed extensive chronic
VHD. All 6 patients with acute GVHD grade II to
V after DLI (5 patients in group A and 1 patient in
roup B) had a relatively short interval between SCT
nd relapse (median, 9 months; range, 5-12 months)
hen compared with patients with no relevant
VHD (median, 17 months; range, 9-66 months).
atient 12 developed transient aplasia of the bone
arrow. Patients 4 and 6 in group A and patient 17 in
roup B developed an idiopathic thrombocytopenic
urpura (ITP) diagnosed by thrombocytopenia in pe-
ipheral blood and sufﬁcient megakaryopoiesis in the
one marrow. None of these 3 patients had detectable
ntiplatelet antibodies. Two patients responded well
o treatment with prednisone, and 1 patient under-
ent splenectomy, after which the platelets normal-
zed. Patient 6 also developed hypothyroidism. Most
atients treated with -IFN developed mild ﬂulike
ymptoms. In 2 patients (patients 5 and 13), severe
ulike symptoms resolved after cessation of the IFN.
urvival
Ten of 13 patients from group A are alive with a
edian follow-up of 62 months (range, 37-102
onths) after DLI. The 1-year overall survival is
00%, 3-year survival is 85%, and 5-year survival is
6% in group A (Figure 2). Two patients from group
died as a result of a gram-negative sepsis while they
ere receiving immunosuppressive treatment for
VHD, and 1 patient died as a result of acute myo-
ardial infarction. In group B, all patients are alive
ith a median follow-up of 20 months (range, 9-35
onths) after DLI.
ISCUSSION
In this study, we pioneered the use of very-low-
ose DLI in combination with -IFN to induce CCR
n patients with a cytogenetic or hematologic response
fter allogeneic SCT and the use of very-low-dose
LI alone in patients with a molecular relapse. We
eport the results of DLI treatment for relapsed CML
atients in our hospital from 1994 to 2003. Up to
999, relapse after allogeneic SCT was diagnosed by w
B&MTorphologic examination, cytogenetic analysis of
lood and marrow cells, or both. In this cohort of
atients with a cytogenetic or a hematologic relapse of
ML-CP after allogeneic SCT (group A), we illus-
rated that the combination of -IFN and very-low-
ose DLI (0.2-0.6  107 CD3 T cells per kilogram)
nduced a rapid and durable CCR in 92% of the
atients. Two patients not continuously receiving
-IFN needed additional doses of DLI to achieve a
CR. CCR occurred at a median of 7 weeks after DLI
or patients with a cytogenetic or a hematologic re-
apse (Table 2). Complete molecular response and
omplete donor chimerism occurred in all patients
ith a CCR (Table 2). Treatment according to this
egimen resulted in an acceptable incidence of both
cute GVHD grade II to IV in 5 of 13 patients and
lso extensive chronic GVHD in 3 of 13 patients
Table 2). From 2000 onward, we monitored CML
atients after allogeneic SCT prospectively with
uantitative BCR/ABL and chimerism measurements
t ﬁxed time points. As a consequence, relapses were
etected at an (earlier) molecular level. Patients with a
olecular relapse were treated with very-low-dose
LI without -IFN, because we assumed that DLI
lone could eradicate the lower tumor mass in molec-
lar relapses compared with the larger tumor mass in
dvanced CML relapses. In case of progression,
-IFN was added to the treatment. Low-dose DLI
ithout -IFN induced a molecular response in 7 of 8
atients with a molecular relapse (group B) with acute
VHD grade III, and extensive chronic GVHD oc-
urred in only 1 of 8 patients (Table 2). The nonre-
ponding patient went into remission when -IFN
igure 2. Survival probability of patients with a relapse of CML
fter allogeneic SCT treated with DLI: Kaplan-Meier curve of
verall survival for group A (cytogenetic or hematologic relapse)
nd group B (molecular relapse) measured in months from ﬁrst
LI.as added to a higher dose of DLI.
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2The CCR rate of 92% accomplished in our study
or hematologic or cytogenetic relapses is similar to
he CCR rates of 57% to 80% reported in the litera-
ure after DLI for patients with relapsed CML in CP
fter allogeneic SCT [3-14]. Mackinnon et al. [6]
eported a mean time of 14 weeks between DLI and
CR for patients treated with 107 donor CD3 T
ymphocytes per kilogram. In this study, patients often
eeded extra infusions with higher doses of T lym-
hocytes and were sometimes also treated with
-IFN, resulting in long intervals between the initial
reatment and remissions. The median time to cyto-
enetic remission in the study of Dazzi et al. [7] was 18
eeks for the group treated with a bulk dose and 22
eeks for the escalated-dose group. We postulated
hat adding -IFN to the treatment with very-low-
ose DLI would decrease the interval between DLI
nd CCR. In our study, we indeed observed a median
ime of 7 weeks between DLI and CCR, which is a
lear difference as compared with the results of Mac-
innon et al. and Dazzi et al. Two patients (patients 5
nd 13) not continuously receiving -IFN needed
xtra doses of DLI and reached their remissions rela-
ively late. These observations support the synergistic
ffect of -IFN with DLI. Moreover, the T-cell dose
dministered (107 MNC per kilogram contain approx-
mately 0.5  107 CD3 cells per kilogram) in our
tudy was approximately 50% lower than the effective
oses in the 2 other studies mentioned [6,7]. Finally,
he median time to molecular response in our study
or patients with a molecular relapse who were treated
y DLI alone (14 weeks) is comparable to the median
ime to molecular response of patients with a hema-
ologic or cytogenetic relapse who were treated with
dditional -IFN (15 weeks). A possible explanation is
hat although the tumor load to be eradicated in pa-
ients with a cytogenetic or hematologic relapse is
igher than in molecular relapses, -IFN accelerated
his eradication.
We also analyzed the effect of -IFN treatment in
ombination with very-low-dose DLI on the inci-
ence of GVHD. The incidences of acute GVHD
rade II to IV in 5 and extensive chronic GVHD in 3
f 13 patients of group A in our study were similar to
hose reported in other studies [3-5,7-14], with the
xception of the study by Mackinnon et al. [6]. Inci-
ences of 33% to 90% of GVHD grade II to IV have
een reported and were correlated with the number of
onor lymphocytes infused [3-5,8-13]. In a recent
arge retrospective study comprising 344 patients with
elapsed CML treated with DLI, a low initial cell dose
f 2  107 MNC per kilogram was associated with
6% GVHD [14]. The median dose of MNC admin-
stered to patients in these studies [3-5,7-14], which
anged from a median of 1.7  108 to 6  108, was
igher than the MNC dose of 0.1  108/kg that our
atients received. These data illustrate that the addi- G
10ion of -IFN to very-low-dose DLI seemed to reduce
he necessity of giving escalating doses of DLI, with
n acceptable incidence of GVHD in patients with a
ematologic or cytogenetic relapse. In other studies,
scalated doses were often necessary after a low initial
ell dose without -IFN [6,7,14]. Finally, we observed
hat a short interval between allogeneic SCT and
elapse was associated with an increased incidence of
igniﬁcant acute GVHD after DLI, especially for cy-
ogenetic and hematologic relapses. Five of 11 pa-
ients who received DLI within 12 months after allo-
eneic SCT developed acute GVHD grade II to IV,
ompared with none of 10 patients who received DLI
ore than 12 months after allogeneic SCT. A possible
xplanation is that antigen-presenting cells, which are
till of recipient origin in the ﬁrst months after allo-
eneic SCT, are gradually replaced by antigen-pre-
enting cells of donor origin during the ﬁrst year after
llogeneic SCT. However, this association was not
ound in 2 recently published analyses of prognostic
actors for acute GVHD after DLI [26,27]. Differ-
nces between those studies and our study population
ere T-cell depletion of the graft and the number of
cells administered with DLI. All our stem cell grafts
ere T-cell depleted, and, therefore, conclusions can
e drawn only for these types of transplants, because
onﬂicting reports have been presented on the re-
ponse rate and incidence of GVHD after DLI. In a
ecent study comprising 593 DLIs, T-cell depletion at
ransplantation was not a signiﬁcant predictor either
or response or for acute GVHD grade II to IV in
ultivariate analysis [27]. In contrast, in another mul-
ivariate logistic analysis of prognostic factors for
cute GVHD after DLI for relapsed CML, T-cell
epletion at transplantation was associated with an
ncreased risk of GVHD after DLI [26].
Because our study was a single-arm prospective
tudy and other studies were retrospective analyses,
nly a comparative trial may give a deﬁnite answer as
o whether the addition of -IFN to very-low-dose
LI is advantageous for treating CML relapses after
llogeneic SCT. The introduction of imatinib, a new
nd highly effective agent against CML, has changed
reatment algorithms for CML already [28]. In a re-
ent study, imatinib seemed to be effective in patients
ith CML who relapsed after allogeneic SCT even
fter failing DLI, without a risk of GVHD [29]. It
ould be of interest to determine in a prospective
omparative trial not only whether the addition of
-IFN to very-low-dose DLI enforces the immune
esponse against CML, but also whether imatinib
iven after SCT might increase the interval between
ransplantation and relapse and thus also the SCT-
LI interval. -IFN might improve the response rate,
hereas imatinib might prolong the interval between
ransplantation and DLI, which is associated with less
VHD, as shown in this study.
p
b
w
b
n
w
r
O
t
o
b
m
a
k
c
s
C
i
G
m
u
a
5
n
s
R
1
1
1
1
1
1
1
1
1
1
2
2
2
-Interferon and CML
BOur observation of the occurrence of ITP in 3
atients, 2 of whom were treated with -IFN, has not
een reported by others as a complication associated
ith DLI therapy for relapse CML. -IFN treatment
y itself has been associated with autoimmune phe-
omena [30], but because in our study 1 patient who
as not receiving -IFN also developed ITP, a cor-
elation with this drug is not a likely explanation.
thers reported aplasia of the bone marrow, with
hrombocytopenia as a consequence [31]. However, in
ur patients, megakaryopoiesis was intact, and throm-
ocytes increased after standard treatment for ITP.
In conclusion, treatment of a cytogenetic or he-
atologic relapse of CML after allogeneic SCT with
combination of very-low-dose DLI (107 MNC per
ilogram, containing approximately 5  106 CD3 T
ells per kilogram) and -IFN resulted in a relatively
hort interval to obtain a durable CCR and molecular
R in 90% of our patients. Furthermore, this reg-
men induced a clinically acceptable rate of acute
VHD, especially when DLI was given more than 12
onths after allogeneic SCT. Patients with a molec-
lar relapse could be effectively and safely treated with
very low dose of DLI containing only approximately
 106 CD3T cells per kilogram.When patients do
ot respond to DLI alone, the addition of -IFN to a
econd dose of DLI could induce a remission.
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